Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19

Benzinga · 1d ago
Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform and raises the price target from $12 to $19.